Cargando…
The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
Anti-estrogens or aromatase inhibitors in combination with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her-2 negative metastatic breast cancer. Although these combination therapies prolong progression-free survival compare...
Autores principales: | Finnegan, Ryan M., Elshazly, Ahmed M., Patel, Nipa H., Tyutyunyk-Massey, Liliya, Tran, Tammy H., Kumarasamy, Vishnu, Knudsen, Erik S., Gewirtz, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890056/ https://www.ncbi.nlm.nih.gov/pubmed/36741704 http://dx.doi.org/10.3389/fonc.2022.966441 |
Ejemplares similares
-
Studies of Non-Protective Autophagy Provide Evidence that Recovery from Therapy-Induced Senescence is Independent of Early Autophagy
por: Saleh, Tareq, et al.
Publicado: (2020) -
ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma
por: He, Ling, et al.
Publicado: (2020) -
Cytoprotective, Cytotoxic and Cytostatic Roles of Autophagy in Response to BET Inhibitors
por: Elshazly, Ahmed M., et al.
Publicado: (2023) -
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023) -
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)